1036 ET - Merck's struggles with Gardasil aren't easing up. The drug maker disclosed 1Q sales of the treatment, which prevents cancers caused from the human papillomavirus, declined 41% to $1.33 billion, due primarily to lower demand in China. Gardasil's challenges were on display in the prior quarter when the company's guidance came up short of Wall Street's estimates and said it was pausing shipments to China of the treatment from February through at least the middle of the year. Gardasil is Merck's biggest-selling franchise behind blockbuster cancer therapy Keytruda, which saw sales increase 4% to $7.21 billion in the quarter. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
April 24, 2025 10:36 ET (14:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。